Kathleen Dungan, MD
Endocrinology, Diabetes & Metabolism · Columbus, OHNPI 1598795098
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $45,848 of the $60,211 with a category attached, or 76.1%. 6 manufacturers reported payments, led by Eli Lilly at 59.8% of the total. Among endocrinology, diabetes & metabolism clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 49 payments — averaging $1228.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$36K
- Insulet Corporation$10K
- Novo Nordisk AS$10K
- Dexcom, Inc.$3K
- Abbott$220
- Lilly USA, LLC$8
Across 216 payments — averaging $6229.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$436K
- Insulet Corporation$323K
- Sanofi-aventis U.S. LLC$279K
- Sequel Med Tech, LLC$165K
- Eli Lilly$59K
- Sanofi US Services Inc.$32K
- plus $50K from 5 others
What the payments were for
- Consulting fees$45,84876%
- Speaking & faculty fees$12,26320%
- Travel & lodging$1,1782%
- Food & beverage$2960%
- Education$4071%
- Other$2200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 25 | $35,988 |
| Insulet Corporation | 14 | $10,488 |
| Novo Nordisk AS | 4 | $10,259 |
| Dexcom, Inc. | 4 | $3,248 |
| Abbott | 1 | $220 |
| Lilly USA, LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$10,289
- TRULICITY$4,200
- DEXCOM G6 TRANSMITTER$3,248
- FREESTYLE COPILOT$220
How this compares
$60,211 in reported general payments places this provider in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $141,944 |
| TrulicityDulaglutide | 119 | $136,255 |
| MounjaroTirzepatide | 116 | $130,811 |
| JardianceEmpagliflozin | 111 | $120,264 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 28 | $84,713 |
| Tresiba Flextouch U-100Insulin Degludec | 73 | $47,510 |
| Tresiba Flextouch U-200Insulin Degludec | 45 | $46,628 |
| Humalog Kwikpen U-200Insulin Lispro | 20 | $44,158 |
| RybelsusSemaglutide | 28 | $38,317 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 39 | $28,953 |
| FarxigaDapagliflozin Propanediol | 18 | $20,696 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $20,286 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $16,163 |
| TradjentaLinagliptin | 23 | $15,244 |
| Novolog FlexpenInsulin Aspart | 39 | $14,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro | $8 | $268,640249 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Columbus
- Elena ChristofidesColumbus$2.3M
- Samuel AndersonColumbus$556K
- Ravi DhawaleColumbus$175K
- Laura RyanColumbus$126K
- Kathleen WyneColumbus$88K
- Jay PatelColumbus$60K
- Lawrence KirschnerColumbus$57K
- Shrikant TamhaneColumbus$55K
- Constantine KroustosColumbus$53K
- Laura ButzColumbus$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.